Optic Atrophy
10
2
2
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (10)
Building Research With Artificial Intelligence in Neuro-Ophthalmology
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for NAION
Stem Cell Ophthalmology Treatment Study II
Natural History Study of FDXR Mutation-related Mitochondriopathy
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy
Computer Aided Diagnosis of Multiple Eye Fundus Diseases From Color Fundus Photograph
Systemic Erythropoietin Injection in Patients Having Optic Atrophy
Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based Therapy
Study the Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Optic Nerve Disease
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients